AIDS · 2017 · 92 citations · 42 references
PharmacyInfectious DiseasesPharmacotherapyClinical PharmacologyHiv ControlVirologyAntiretroviral TherapyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyLipid-lowering TherapyAntiviral Safety AssessmentAntiviral TherapeuticsHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyNon-nucleoside Reverse Transcriptase InhibitorsPharmacodynamics Of Antiretroviral TherapyViral Disease Suppression
OBJECTIVE: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. METHODS: HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. Patients were randomized to switch to DTG or to remain on PI/r. Primary endpoints were: proportion maintaining HIV RNA less than 50 copies per ml and percentage change from baseline of total cholesterol at week 48. RESULTS: In total, 415 patients (32 sites in six European countries) were randomized: 205 to DTG and 210 to continue PI/r. About 89% were men, 87% more than 50 years, 74% had a Framingham score more than 10%, with a median CD4 cell count of 617 cells per μl and suppressed viremia for a median of 5 years. At week 48, in the intent-to-treat analysis, treatment success rate was 93.1% in DTG group and 95.2% in PI/r group (difference -2.1%, 95% confidence interval -6.6 to 2.4, noninferiority demonstrated). There were four virological failures with DTG and one with PI/r with no emergent resistance mutations. There was no significant difference in severe adverse events or grade 3 or 4 adverse events or treatment modifying adverse events. Total cholesterol and other lipid fractions (except high-density lipoprotein cholesterol) improved significantly (P < 0.001) in the DTG group regardless of PI/r at baseline. CONCLUSION: Switching to a DTG regimen in virologically suppressed HIV type 1 patients with high cardiovascular disease risk was noninferior, and significantly improved lipid profiles.
42
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Sharon Walmsley, Antonio Antela, Nathan Clumeck et al. · New England Journal of Medicine · 2013 · 878 citations · Full text
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Huldrych F. Günthard, Michael S. Saag, Constance A. Benson et al. · JAMA · 2016 · 656 citations · Full text
Signe Westring Worm, Caroline Sabin, Rainer Weber et al. · The Journal of Infectious Diseases · 2009 · 647 citations · Full text
François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 546 citations · Full text